Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

American Society of Clinical Oncology (ASCO) - Tập 21 Số 6 - Trang 976-983 - 2003
I. Craig Henderson1, Donald A. Berry1, George D. Demetri1, Constance Cirrincione1, Lori J. Goldstein1, Aña Lluch1, James N. Ingle1, M. Robert Cooper1, Daniel F. Hayes1, Katherine H. R. Tkaczuk1, Gini F. Fleming1, James F. Holland1, David B. Duggan1, John T. Carpenter1, Emil Frei1, Richard L. Schilsky1, William C. Wood1, Hyman B. Muss1, Larry Norton1
1From the University of California at San Francisco, San, Francisco, CA; Cancer and Leukemia Group B (CALGB) Statistical Center, Durham; Wake Forest University School of Medicine, Winston-Salem, NC; University of Texas M.D. Anderson Cancer, Houston; Southwest Oncology Group Operations, San, Antonio, TX; Dana-Farber Cancer Institute, Boston, MA; Eastern Cooperative Oncology Group Operations, Philadelphia, PA; North Central Cancer Treatment Group Operations, Rochester, MN; Georgetown University Medical...

Tóm tắt

Purpose: This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival. Patients and Methods: After surgical treatment, 3,121 women with operable breast cancer and involved lymph nodes were randomly assigned to receive a combination of cyclophosphamide (C), 600 mg/m2, with one of three doses of doxorubicin (A), 60, 75, or 90 mg/m2, for four cycles followed by either no further therapy or four cycles of paclitaxel at 175 mg/m2. Tamoxifen was given to 94% of patients with hormone receptor–positive tumors. Results: There was no evidence of a doxorubicin dose effect. At 5 years, disease-free survival was 69%, 66%, and 67% for patients randomly assigned to 60, 75, and 90 mg/m2, respectively. The hazard reductions from adding paclitaxel to CA were 17% for recurrence (adjusted Wald χ2 P = .0023; unadjusted Wilcoxon P = .0011) and 18% for death (adjusted P = .0064; unadjusted P = .0098). At 5 years, the disease-free survival (± SE) was 65% (± 1) and 70% (± 1), and overall survival was 77% (± 1) and 80% (± 1) after CA alone or CA plus paclitaxel, respectively. The effects of adding paclitaxel were not significantly different in subsets defined by the protocol, but in an unplanned subset analysis, the hazard ratio of CA plus paclitaxel versus CA alone was 0.72 (95% confidence interval, 0.59 to 0.86) for those with estrogen receptor–negative tumors and only 0.91 (95% confidence interval, 0.78 to 1.07) for patients with estrogen receptor–positive tumors, almost all of whom received adjuvant tamoxifen. The additional toxicity from adding four cycles of paclitaxel was generally modest. Conclusion: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(98)03301-7

10.1200/JCO.1990.8.9.1483

10.1093/jnci/83.24.1797-a

Seidman AD, Norton L, Reichman BS, et al: Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 20:40,1993–45,

Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): An Intergroup trial. Proc Am Soc Clin Oncol 16:1a,1997, (abstr 2)

10.1200/JCO.2000.18.4.724

10.1056/NEJM199405053301801

10.1093/jnci/90.16.1205

10.1200/JCO.1997.15.5.1858

10.1200/JCO.1999.17.11.3374

Coates AS, Gelber RD, Goldhirsch A: Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet 352:1783,1998–1784, (letter)

10.1200/JCO.1998.16.11.3493

Fumoleau P, Brémond A, Kerbrat P, et al: Better outcome of premenopausal node-positive (N+) breast cancer patients (pts) treated with 6 cycles vs 3 cycles of adjuvant chemotherapy: Eight year follow-up results of FASG 01. Proc Am Soc Clin Oncol 18:67a,1999, (abstr 252)

10.7326/0003-4819-96-2-133

10.1093/jnci/92.3.225

10.1016/S0140-6736(98)01350-6

10.1016/S0140-6736(00)02841-5

Peters W, Rosner G, Vredenburgh J, et al: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a,1999, (abstr 2)

Rodenhuis S, Bontenbal M, Beex LVAM, et al: Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc Am Soc Clin Oncol 19:74a,2000, (abstr 286)

10.1056/NEJM199405053301802

10.1093/jnci/90.18.1346

Buzdar AU, Singletary SE, Valero V, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073,2002–1079,

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 21 Số 6

976-983

Thông tin tác giả